Author

Carol Ruffell

Institution: Drugs for Neglected Diseases Initiative

Observed institutions: Drugs for Neglected Diseases Initiative, Global Antibiotic Research & Development Partnership

ORCID: 0000-0002-3180-7574

Observed ORCID: 0000-0002-3180-7574

OpenAlex ID: A5016726832

Paving the way for affordable and equitable liposomal amphotericin B access worldwide

2024 · Janice Soo Fern Lee, Rachel M Cohen, et al. · The Lancet Global Health · 48

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme

2020 · Amir Shroufi, Nelesh P. Govender, et al. · International Journal of Infectious Diseases · 11

Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers

2024 · Vishal Goyal, Edrich Krantz, et al. · Clinical and Translational Science · 5

Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis

2024 · Nabila Ibnou Zekri Lassout, Vishal Goyal, et al. · Clinical and Translational Science · 2

Works count: 4

Citation count: 66

H-index: 3

I10-index: 2